CD8 T cells play a critical role in responses of TILs due to BRAF inhibition. CD8 T cells play a critical role in responses of TILs due to BRAF inhibition.

Slides:

Advertisements

Similar presentations

Synergistic antitumor effect of anti-CD40/CpG and 14

Advertisements

Antitumor effect of the combination of IL-2 IC and anti–CTLA-4.

Selinexor combines with immune checkpoint blockade to slow B16F10 melanoma tumor growth. Selinexor combines with immune checkpoint blockade to slow B16F10.

Anti-CD40 and CpG induce activation of T cells in draining lymph nodes

Anti–4-1BB/PD-1 combination enriched CD8+ T cells in TILs

by Bindu Varghese, Adam Widman, James Do, Behnaz Taidi, Debra K

Frequencies of immune cell types show much stronger variations between tumor types in the tumor infiltrate compared with the spleen and tumor-draining.

Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.

H31m1-PDL1 cells form progressively growing tumors in WT mice.

Tumor development of poorly immunogenic LLC and B16F10 cells modified to produce GM-CSF was markedly inhibited. Tumor development of poorly immunogenic.

Increased chemokine content and leukocyte infiltrate in D6-negative tumors. Increased chemokine content and leukocyte infiltrate in D6-negative tumors.

B7-H4 expression correlates with MHC-I expression and improved prognosis in patients with breast cancer. B7-H4 expression correlates with MHC-I expression.

Fig. 5 Combination intravenous reovirus and checkpoint inhibition in an orthotopic syngeneic brain tumor model. Combination intravenous reovirus and checkpoint.

Antitumor effect of local cancer immunotherapy treatment toward distant B16F10 tumors. Antitumor effect of local cancer immunotherapy treatment toward.

Anti-CD20 CAR exPBNK significantly inhibit growth of Raji cells in xenografted mice. Anti-CD20 CAR exPBNK significantly inhibit growth of Raji cells in.

Anti-CD96 combines with anti–CTLA-4 or anti–PD-1 to suppress experimental and spontaneous lung metastases. Anti-CD96 combines with anti–CTLA-4 or anti–PD-1.

PD-1–PD-L1 axis is highly expressed and is not IFNγ-dependent in a subcutaneous murine model of PDA. A, experimental design for establishment of subcutaneous.

CD8+ T cells were immunomodulated and required for the efficacy of anti–4-1BB/anti–PD-1 combination treatment. CD8+ T cells were immunomodulated and required.

Mouse lymphoma model. Mouse lymphoma model. A, EL-Arf−/− cells (1 × 106) were tail-vein injected into C57BL/6 mice. LNIWC imaging was separated into 2.

CPI-444 efficacy requires CD8+ T cells and is associated with increased CD73 expression. CPI-444 efficacy requires CD8+ T cells and is associated with.

Exosome-mediated inhibition of T cells is reversible.

Fig. 2 In situ vaccination of CpG in combination with anti-OX40 antibody cures established local and distant tumors. In situ vaccination of CpG in combination.

Dox administration was required for Tet-CD19CAR T cells to show a suppressive function against a CD19+ tumor in vivo. Dox administration was required for.

Mice immunized twice with RRBC showed superior protection to tumor challenge with αGal-positive MC38 colon carcinoma cells compared with mock-immunized.

Combined BRAFi and anti-CTLA4 administration leads to prolonged antitumor immunity in a patient with metastatic melanoma. Combined BRAFi and anti-CTLA4.

coTCRcys-transduced T cells control tumor growth in vivo.

Stereotactic radiotherapy increases Tregs in tumors.

Antitumor activity of KM100+5 μmol/L MTX treatment in the presence or absence of CD8+ T cells in BALB-neuT mice bearing subcutaneous tumors of TUBO cells.

The selective depletion of DTR-expressing FAP+/CD45+ and FAP+/CD45− tumoral cells from bone marrow chimeric mice by the administration of DTX. A, sketch.

Immune signatures of patients with short-, medium-, and long-term survival. Immune signatures of patients with short-, medium-, and long-term survival.

Anti-Flk-1 treatment inhibits growth of s. c. 4T1 and B16 tumors. s. c

PD-1 inhibition stimulates the proliferation and cytokine secretion of exhausted/senescent CD8+ T cells in vitro. PD-1 inhibition stimulates the proliferation.

Experimental metastasis inhibition by primary tumors is mediated by NK cells and IFNγ. Experimental metastasis inhibition by primary tumors is mediated.

Anti-Flk-1 mAb inhibits vascularization of Matrigel plugs.

PD-L1 expressed on edited T3 sarcoma cells prevents their immune elimination. PD-L1 expressed on edited T3 sarcoma cells prevents their immune elimination.

PVHA increased anti-PD-L1–mediated growth inhibition in 4T1/HAS3 tumors. PVHA increased anti-PD-L1–mediated growth inhibition in 4T1/HAS3 tumors. A, 4T1/HAS3.

ADU-S100–mediated tumor clearance is dependent on CD4+, CD8+ T cells, and NK cells. ADU-S100–mediated tumor clearance is dependent on CD4+, CD8+ T cells,

CD4+ and CD8+ TILs express surface CD137.

MEDI4736 shows antitumor activity in xenograft mouse models of human cancer. MEDI4736 shows antitumor activity in xenograft mouse models of human cancer.

Dual blockade of PD-1 and CTLA-4 directly activates CD4+Foxp3− cells in the absence of CD8+ or CD4+Foxp3+ cells. Dual blockade of PD-1 and CTLA-4 directly.

ESKM is superior to ESK1 in vivo, and is effective against multiple tumor models. ESKM is superior to ESK1 in vivo, and is effective against multiple tumor.

M-CSFR inhibition decreases tumor-associated macrophages in mesothelioma and improves the DC therapy induced CD8+ T-cell phenotype. M-CSFR inhibition decreases.

Efficacy of DC therapy is synergistically enhanced by combination therapy with TAM depletion in mesothelioma mouse models. Efficacy of DC therapy is synergistically.

Combination CDN and PD-L1 mAb treatment of established MOC1 tumors produces consistent tumor rejection. Combination CDN and PD-L1 mAb treatment of established.

The responses of H292 and A549 lung cancer xenografts to hypofractionated radiation were enhanced by the ketogenic diet. The responses of H292 and A549.

CD4+ cells are required to generate protective immunity against the MT-HA tumor in HA104 mice. CD4+ cells are required to generate protective immunity.

DAC treatment alters immune cell composition and enhances cytokine production in the peritoneal lavage. DAC treatment alters immune cell composition and.

Immunophenotypic analysis of TILs in B16 and K1735 melanoma following combination therapy with antibodies targeting PS and PD-1. Immunophenotypic analysis.

In vivo bioluminescence imaging of primary tumors and tumor metastasis

Mice treated with DC therapy and/or M-CSFR inhibition were protected from tumor rechallenge with combination therapy-treated mice displaying superior recall.

Tumor-resident CD8+ T cells rapidly expand after IL-15/IL-15Rα complex treatment. Tumor-resident CD8+ T cells rapidly expand after IL-15/IL-15Rα complex.

Anti-SEMA4D antibody regulates immune-cell infiltration and inhibits growth of Tubo.A5 orthotopic mammary carcinoma. Anti-SEMA4D antibody regulates immune-cell.

Effect of inhibiting HO-1 on adaptive immune- and cytokine-dependent regulation of tumor growth. Effect of inhibiting HO-1 on adaptive immune- and cytokine-dependent.

MDSC-derived IL-6 enhances tumor progression through the inhibition of tumor-specific TH1 development and of their helper activity for CD8+ T cells. MDSC-derived.

Comparison of in vivo activity of 4D5scFvZZ and 4D5scFv.

Tumor protection induced by therapeutic PLG vaccination in combination with blockade antibodies. Tumor protection induced by therapeutic PLG vaccination.

Model of minimal residual disease.

TCR stimulation by agonistic mAb in vivo administration inhibits mouse T-ALL development. TCR stimulation by agonistic mAb in vivo administration inhibits.

Anti-CD40 activates TAMs and recruits inflammatory monocytes.

Comparative effect of anti-TIM3 against experimental tumors.

Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors. Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors.

Targeting GAPLINC decreased CD44 expression and tumor growth in vivo.

Proliferation of TA3-Ha and TA3-St cells in vitro and in vivo.

The effect of TGFβ on the post-RT increase of Tregs in tumors.

Intratumoral injections of small doses of agonist anti-CD137 mAb to directly act on CD137+ TILs render systemic immunotherapeutic effects that are synergistic.

Moderate-affinity vaccine antigens elicited greatest antitumor response. Moderate-affinity vaccine antigens elicited greatest antitumor response. Wild-type.

Enhanced antitumor effects with combination IL21 and anti–PD-1/anti–Tim-3 therapy. Enhanced antitumor effects with combination IL21 and anti–PD-1/anti–Tim-3.

IL2Cx alone or in combination with anti–CTLA-4 increases the CD8/Treg ratio in the tumor. IL2Cx alone or in combination with anti–CTLA-4 increases the.

Depletion of CD8+, CD4+, and Ly6G+ cells in subcutaneous TUBO tumor-bearing BALB/c mice treated with KM100 + MTX. Depletions were conducted by intraperitoneal.

Parthenolide inhibits tumor promotion and increases p21 expression in vivo. Parthenolide inhibits tumor promotion and increases p21 expression in vivo.

Presentation transcript:

CD8 T cells play a critical role in responses of TILs due to BRAF inhibition. CD8 T cells play a critical role in responses of TILs due to BRAF inhibition. A, schema for CD8 T cell-depletion in BP tumors. BP cells (8 × 105) were subcutaneously injected into C57BL/6 mice, and BRAFi administration (200 ppm) was initiated at day 0. Two hundred micrograms of rat anti-mouse CD8, or isotype antibody was administered intraperitoneally 1 day before tumor implantation and every 3 to 4 days thereafter. B, analysis of CD4+ and CD8+ T cells in the draining lymph node and tumor was done on days 3, 7, and 11 after the initiation of BRAFi for CD8 T-cell depletion by flow cytometry using a different anti-CD8 clone. Representative plots at day 3 are shown. C, effects of CD8 depletion on survival of mice given BP tumor with or without BRAFi therapy displayed in a Kaplan–Meier plot. *, P < 0.05 comparing BRAFi treated mice with control mice. D, tumor volumes from experiments as in C measured every 3 to 4 days. *, P < 0.05 comparing BRAFi + isotype–treated mice to BRAFi + anti-CD8 mAb–treated mice. Representative of three experiments. Zachary A. Cooper et al. Cancer Immunol Res 2014;2:643-654 ©2014 by American Association for Cancer Research